10-K: Prestige Consumer Healthcare Reports FY26 Results

Prestige Consumer Healthcare Inc. announced its fiscal year 2026 results, showing a decrease in total revenues and gross profit, impacted by supply chain challenges and acquisition costs.

Summary

• Prestige Consumer Healthcare Inc. reported total revenues of $1.089 billion for the fiscal year ended March 31, 2026, a decrease of 4.3% from the prior year.
• Gross profit decreased by 6.1% to $595.6 million, with gross profit margin declining to 54.7% from 55.8% in the previous year.
• Contribution margin also saw a decrease of 6.7% to $446.8 million.
• The North American OTC Healthcare segment experienced a 4.8% revenue decline, primarily due to lower sales in the Eye & Ear Care category.
• The International OTC Healthcare segment saw a 1.5% revenue decrease.
• General and administrative expenses increased due to higher compensation costs, acquisition-related expenses, and an increased allowance for doubtful accounts.
• The company completed the acquisition of Pillar5 Pharma Inc. in December 2025 and entered into an agreement to acquire a portfolio of brands from Foundation Consumer Brands, LLC in March 2026.
• Net cash provided by operating activities increased slightly to $257.6 million.
• Net cash used in investing activities significantly increased to $136.8 million, largely due to acquisitions.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the reported decline in revenues and profitability, coupled with increased expenses and ongoing supply chain challenges, despite strategic acquisitions.

Positives

• Net cash provided by operating activities increased by $6.1 million to $257.6 million for fiscal year 2026.
• The company maintained compliance with its debt covenants.
• The company completed the acquisition of Pillar5 Pharma Inc., a sterile ophthalmic manufacturer, in December 2025.
• A definitive agreement was entered into to acquire a portfolio of over-the-counter consumer health products, including Breathe Right and Dimetapp brands, from Foundation Consumer Brands, LLC, expected to close in the first half of fiscal 2027.
• The company's share repurchase program continued, with $156.3 million spent on repurchases in fiscal year 2026.

Negatives

• Total revenues decreased by 4.3% to $1.089 billion in fiscal year 2026.
• Gross profit decreased by 6.1% to $595.6 million, and gross profit margin declined to 54.7% from 55.8%.
• Contribution margin decreased by 6.7% to $446.8 million.
• The North American OTC Healthcare segment revenue decreased by 4.8%, primarily due to supply constraints in the Eye & Ear Care category.
• The International OTC Healthcare segment revenue decreased by 1.5%.
• General and administrative expenses increased by $8.2 million, driven by compensation, acquisition costs, and a higher allowance for doubtful accounts.
• A supplier loan of $10.3 million was written off in fiscal year 2026.
• The company recognized impairment charges of $12.5 million in fiscal year 2025 for non-strategic intangible assets.
• The effective tax rate increased to 26.1% in fiscal year 2026 from 24.5% in fiscal year 2025.

Risks

• Dependence on third-party manufacturers for product supply, with past difficulties in meeting demand causing shortages, particularly for eye care products.
• Potential for price increases from suppliers due to raw materials, labor, energy, and transportation costs, which may not be fully offset by pricing actions.
• High level of competition in the OTC health and personal care market from larger companies with greater resources.
• Reliance on a limited number of key customers, including Walmart and Amazon, for a significant portion of gross revenues.
• Disruptions in third-party distribution centers or manufacturing facilities could prevent meeting customer demand.
• Cybersecurity threats and the potential for data breaches impacting operations and reputation.
• Evolving data privacy laws and regulations in the U.S. and abroad, with potential for significant costs and liabilities.
• Significant indebtedness, with total debt of approximately $1.0 billion at March 31, 2026, and an expected increase to $2.2 billion upon closing the Foundation Consumer Brands acquisition.
• Restrictive covenants in debt agreements that may limit corporate actions such as acquisitions, dividend payments, and debt incurrence.
• Potential for product liability claims, product recalls, and related negative publicity.
• Inability to protect intellectual property rights or maintain necessary license agreements.
• The majority of assets consist of goodwill and intangible assets, which are subject to impairment risk.
• The company is subject to increasing focus on environmental and sustainability issues, with potential for reduced demand if expectations are not met.

Future Outlook

The company expects economic conditions to remain volatile and uncertain, potentially impacting prices, supply, and demand for its products. Shortages of certain products, particularly eye care, are expected to continue to negatively impact sales. The company anticipates that its top ten customers, including Walmart and Amazon, will continue to account for a large portion of sales.

Management Comments

• We believe that our product portfolio is positioned for long-term growth based on the following factors: Diversified Portfolio of Well-Recognized and Established Consumer Brands.
• We believe we are well positioned in these categories due to the long history and consumer awareness of our brands, our strong market positions and our low-cost operating model.
• Acquisitions are a part of our overall strategy for growing revenue. We have a history of growth through acquisitions.
• We believe our business model allows us to integrate acquisitions in an efficient manner, while also providing opportunities to realize significant cost savings.
• Management believes that maintaining open communication, fair employment practices, and consistent application of policies supports positive employee relations and contributes to employee engagement and retention.

Industry Context

StockSavvy.ai notes that Prestige Consumer Healthcare operates in the highly competitive OTC health and personal care market, facing challenges from both branded and private label competitors. The company's strategy of acquiring and revitalizing established brands, coupled with investments in marketing and distribution, positions it to navigate industry trends, though supply chain disruptions and economic volatility present ongoing risks.

Comparison to Industry Standards

• The company's gross profit margin of 54.7% for FY2026 is within the typical range for consumer staples companies, but it has seen a slight decline from the previous year.
• The decline in revenue and contribution margin, particularly in the Eye & Ear Care category, highlights industry-wide supply chain challenges affecting product availability, a common issue reported by competitors.
• The company's reliance on major retailers like Walmart and Amazon (20% and 15% of revenue, respectively) is consistent with industry trends where large retailers dominate distribution channels for consumer packaged goods.
• The company's strategy of acquiring brands from larger companies that may have considered them non-strategic is a common approach in the consumer goods sector to unlock value.

Legal Proceedings

• The company is involved in routine legal matters and other claims incidental to its business, which are reviewed internally and with external counsel. The resolution of these matters is not expected to have a material adverse effect on the company's financial condition or results of operations.

Stakeholder Impact

• Shareholders may see a negative impact on stock price due to the reported decline in financial performance and ongoing risks.
• Employees may be affected by increased general and administrative expenses related to compensation and acquisition costs.
• Customers may experience continued product shortages, particularly in the Eye & Ear Care category, impacting availability.
• Suppliers may face increased scrutiny and potential financial support requests, as evidenced by the write-off of a supplier loan.

Next Steps

• Complete the acquisition of the Foundation Consumer Brands product portfolio in the first half of fiscal 2027.
• Continue to invest in brand development through new product lines, extensions, and advertising support.
• Expand international sales by growing the number of brands sold through existing distribution networks and identifying new partners.
• Integrate acquired businesses efficiently and realize cost savings.
• Continue to focus on expanding direct sales while reducing reliance on brokers.
• Invest in enhancements and capabilities at the acquired Canadian manufacturing facility to improve supply consistency and reliability.

Key Dates

Recommendation

While the company is executing strategic acquisitions and has a strong brand portfolio, the reported decline in revenue and profitability, coupled with persistent supply chain issues and increased costs, warrants a cautious approach. The significant debt load and integration risks associated with upcoming acquisitions suggest a 'hold' rating until clearer signs of recovery and successful integration emerge.

Keywords

Prestige Consumer Healthcare, 10-K, Annual Report, OTC Healthcare, North American OTC Healthcare, International OTC Healthcare, Pillar5 acquisition, Foundation Consumer Brands acquisition, financial results, revenue, gross profit, contribution margin, supply chain, debt, goodwill impairment